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ABSTRACT
An effective preventive vaccine is highly sought after in order to stem the current HIV-1 pandemic. Both conservation of contig-
uous gp41 membrane-proximal external region (MPER) amino acid sequences across HIV-1 clades and the ability of anti-MPER
broadly neutralizing antibodies (BNAbs) to block viral hemifusion/fusion establish theMPER as a prime vaccination target. In
earlier studies, we described the development of anMPER vaccine formulation that takes advantage of liposomes to array the
MPER on a lipid bilayer surface, paralleling its native configuration on the virus membrane while also incorporating molecular
adjuvant and CD4 T cell epitope cargo. Here we demonstrate that several immunizations withMPER/liposomes induce high lev-
els of bone marrow long-lived plasma cell (LLPC) antibody production. Single-cell immunoglobulin gene retrieval analysis
shows that these plasma cells are derived from a germ line repertoire of B cells with a diverse representation of immunoglobulin
genes, exhibiting antigen-driven positive selection. Characterization of LLPC recombinant monoclonal antibodies (rMAbs) indi-
cates that antigen recognition is achieved through convergence on a common epitopic focus by utilizing various complementari-
ty-determining region H3 (CDRH3) lengths. Importantly, the vast majority of rMAbs produced from these cells lack polyreactiv-
ity yet manifest antigen specificity in the context of lipids, shapingMPER-specific paratopes through selective pressure. Taken
together, these findings demonstrate that the MPER is a vaccine target with minimal risk of generating off-target autoimmunity.
IMPORTANCE
A useful vaccine must generate desired long-term, antigen-specific antibody responses devoid of polyreactivity or autoreactivity.
The common polyreactive features of some HIV-1 BNAbs have raised concern about elicitation of anti-MPER antibodies. Utiliz-
ing single-LLPC repertoire analysis and biophysical characterization of anti-MPER rMAbs, we show that their fine specificities
require a structural fitness of the antibody combining site involving heavy and light chain variable domains shaped by somatic
hypermutation and affinity maturation of B cells in the germinal center. Perhaps more importantly, our results demonstrate that
the majority of MPER-specific antibodies are not inherently polyspecific and/or autoreactive, suggesting that polyreactivity of
MPER-specific antibodies is separable from their antigen specificity.
To date, no widely applicable cure for HIV-1 is known, andcurrent preventive efforts have not proven completely effec-
tive. Successful vaccinationwould be a powerfulmeans to fight the
global HIV-1 pandemic. Unlike infectious diseases against which
vaccines induce highly protective immunity (1), broad and potent
neutralization of HIV-1 strains has not been elicited through vac-
cination with HIV-1 protein envelope (Env) subunits or inacti-
vated virus. However, the discovery of numerous broadly neutral-
izing antibodies (BNAbs) capable of blocking viral binding to or
entry into host cells suggested that vaccination is a promising
strategy (2–4).
TheHIV-1 envelope spike protein, comprised of trimeric gp41
and gp120 subunits, is the only viral target exposed on the virion
membrane surface and therefore is the singular focus for an anti-
body-based vaccine. The first HIV-1 BNAb discovered, 2F5, is
specific for themembrane-proximal external region (MPER), and
more recently, the MPER-specific neutralizing antibody list has
grown to include 4E10, Z13e1, m66, m66.6, 10E8, and CAP206-
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CH12 (5–12). The BNAb list has also widened over time with the
identification of a variety of other targets, including the CD4-
binding site, the V1/V2-glycan-containing epitope, the V3-gly-
can-containing epitope, and gp120/gp41-bridging epitopes.
These BNAbs were discovered through the recovery of single
memory B cells from infected individuals and by recombinant
monoclonal antibody (rMAb) production (reviewed in references
2, 13, and 14). Nevertheless, as one of the most highly conserved
regions on the envelope spike, the MPER remains an exemplary
vaccine target (9, 15, 16).
The MPER is a hydrophobic and tryptophan-rich segment of
22 amino acids located immediately external to the transmem-
brane (TM) domain of gp41 (15, 17). Structurally, theMPER con-
sists of two alpha-helices connected by a linker in a helix-hinge-
helixmotif in a lipid environment (16, 18).We previously showed
that the BNAbs 2F5 and 4E10 mediate extraction of their epitopic
residues on the MPER helices from the lipid membrane (18–20).
Very recently, the first micelle-embedded trimer spike structure
that includes the MPER and TM regions was elegantly solved us-
ing cryo-electron microscopy (cryo-EM), and this structure sug-
gests that in a 10E8-bound conformation, the MPER is lifted up
off the membrane (21). A recent crystallographic analysis identi-
fied a lipid as an integral component of the 4E10 BNAb and im-
plied a similar MPER segment extraction geometry out of the
membrane (22). Functionally, the MPER has been shown to be
required for both hemifusion and fusion processes preceding
viral entry (15–17, 23–25), presumably through its strong in-
teraction with the membrane. Therefore, antibodies elicited by
vaccination that bind with high affinity to the MPER on the
trimer would impede or block MPER function and manifest
neutralizing activity.
Extensive biochemical and structural analyses of MPER-spe-
cific BNAbs have suggested the obligate role of the membrane
environment in MPER immunogen design, both to configure na-
tive MPER structure and to induce potent BNAbs (18, 19, 22,
26–35). Such requirements are likely explanations for the lack of
anti-MPER neutralizing antibodies elicited through vaccination
with free MPER peptides, MPER epitope mimetics, or MPER
epitopes grafted onto protein scaffolds (28, 36–38; reviewed in
reference 39). Nonetheless, while liposome-basedMPER vaccines
induce strong MPER antibody responses (40–45), the chemical
modifications used for membrane anchoring and prevention of
proteolysis, such as palmitic acid adducts and amide capping, re-
spectively, have an impact on antigenic determinants even with-
out inducing alterations in the MPER segment structure (42).
These challenges for membrane-arrayed MPER segment im-
munogen design still await innovative solutions. Moreover, it has
been proposed that sequence similarity of endogenous mamma-
lian proteins to the MPER limits expansion of B cells expressing
germ line-encodedMPER-reactive B cell receptors (BCR) because
of negative selection during development (46, 47). It has further
been suggested that HIV-1 Env gp41 antibodies might arise from
polyreactive B cells, possibly from the pool of gut microbe-regu-
lating B cells (48, 49). This notionmight explainwhy acutelyHIV-
1-infected subjects have antibodies whose unmutated ancestors
react with bacterial or host antigens but not with the HIV-1 enve-
lope. The highly polyreactive nature of theMPER BNAbs 2F5 and
4E10 has been construed as evidence for the existence of such a
pathway (47, 50, 51). These are sound proposals; however, given
the ability of certain BNAbs, notably 10E8, to arise independently
of polyreactivity (6), it is not a sine qua non that a successfulMPER
immunogenmust elicit antibodies with this characteristic in order
to be broadly neutralizing.
In this study, we experimentally assessed the extent to which du-
rable, affinity-matured anti-MPER antibody responses induced by
MPER/liposome vaccination exhibit polyreactivity. We demon-
strated that MPER/liposome immunizations generate MPER-spe-
cific bone marrow (BM) long-lived plasma cell (LLPC)-derived
class-switched Abs. Single-plasma-cell analysis followed by im-
munoglobulin gene rescue and sequencing and analysis of ex-
pressed rMAbs revealed that BM LLPC use a diverse collection of
immunoglobulin genes with the same epitope specificity, but with
functionally distinct characteristics. Affinity maturation of multi-
ple distinct B cells postimmunization and -boosting yielded
MPER epitope specificity through structural fitness and conver-
gence on a common antigenic determinant, accompanied by little,
if any, polyreactivity for 39 of 44 rMAbs analyzed. These charac-
teristics demonstrate thatMPER specificity is not defined by poly-
reactivity for the vast majority of rMAbs elicited by vaccination
that recognize membrane-embedded MPER.
MATERIALS AND METHODS
Mice and MPER/liposome immunizations. BALB/c mice were obtained
fromTaconic Biosciences (Hudson,NY). Allmice usedwere 8 to 10weeks
of age at the time of initial immunization. Mice were housed in a specific-
pathogen-free facility andmaintained in accordance with procedures and
protocols approved by the Dana-Farber Cancer Institute and Harvard
Medical School Animal Care and Use Committee Institutional Review
Board. Immunization liposomes were made as described before (42) by
drying the following components under a nitrogen stream and placing
them under vacuum overnight: N- or C-terminally palmitoylated MPER
peptides (Npalm-MPER or Cpalm-MPER), monophosphoryl lipid A
(MPLA) from Salmonella enterica serotypeMinnesota (Sigma-Aldrich, St.
Louis, MO), and the lipids 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), and
1,2-dioleoyl-sn-glycero-3-phospho-(1=-rac-glycerol) (DOPG) (Avanti
Polar Lipids Inc., Alabaster, AL) at a 2:2:1 ratio. Liposomes were formed
with encapsulated LACK1 peptide by rehydration with phosphate-buff-
ered saline (PBS) containing 1,000g/ml LACK1 to a final total liposome
component of 25.2mg/ml. Final liposomes incorporatedMPER at a 1:200
molar ratio (MPER:lipid) and contained 175 g/ml MPLA, with a total
lipid concentration of 25 mg/ml. MPER/liposomes were sized by vortex-
ing 6 times for 30 s each at 5-min intervals, 6 rounds of flash freezing in
liquid nitrogen and thawing at 37°C, and extrusion by passage through a
100-nm-pore-size polycarbonate membrane 21 times. Mice were immu-
nized intradermally with 50 l per hind flank. Unless noted otherwise,
immunizations were administered on three occasions at 21-day intervals.
Microengraving and single-B-cell isolation. Npalm-MPER/lipo-
somes, consisting of MPER at a 1:50 molar ratio with DOPC and DOPG
lipids (4:1) at a final total liposome component of 2 mg/ml, were rehy-
drated by vortexing, freeze-thawing, and extrusion as described above.
Polylysine-coated glass slides (25 75 1mm)were incubated overnight
with rocking at room temperature, submerged in 100g/ml liposomes in
PBS. The liposome solution was poured off, and slides were blocked for
1 h in a 3% milk-0.05% Tween 20-PBS solution with rocking at room
temperature. Polymethylsiloxane microwell molds were prepared as de-
scribed in detail by Ogunniyi et al. (52). Molds were subjected to plasma
cleaning under vacuum to charge and sterilize the surface and then were
blocked with 1% bovine serum albumin (BSA) in PBS for 20 min. The
blocking solution was rinsed from slides with purified water. CD138
plasma cells were sorted from the BM of femurs and tibias from one
mouse by use of a Miltenyi Biotec (Bergisch Gladbach, Germany) mag-
netic bead labeling and enrichment kit. The mold was removed from
blocking buffer and the liquid aspirated, followed by three washes with
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10% fetal bovine serum containing 1% penicillin-streptomycin in RPMI
1640 (growth medium). The growth medium was aspirated, and plasma
cells (100,000 in 300 l growth medium) were distributed dropwise
evenly across the mold. The growth medium in the mold was aspirated,
and growth medium was distributed onto the mold surface. The medium
was then aspirated, and growth medium plus 100 ng/ml interleukin-6
(IL-6) was distributed on the mold before the MPER/liposome-labeled
slide was placed on the mold and clamped in place in a hybridization
chamber for 1 h at 37°C. Following incubation, the slide was washed and
blocked, and secondary antibody (goat anti-mouse IgG–AF647 and anti-
IL-6–AF488) hybridization was carried out in a Tecan HS 400 Pro slide
washer (Tecan, Mannedorf, Switzerland). Microarray analysis of slides
was performed using a GenePix 4400 instrument (Molecular Devices
LLC, Sunnyvale, CA) at 488 nm and 635 nm, and identification of wells
containingMPER-specific cells was performed using GenePix Pro 6 anal-
ysis software. Themoldwith plasma cells was stored submerged in growth
medium at 4°C overnight, and single plasma cells were isolated by use of a
micromanipulator and placed into 96-well plates containing a solution of
1 l RNasin Plus RNase inhibitor (Promega, Madison, WI) and 9 l
UltraPure DNase-/RNase-free H2O (Life Technologies, Grand Island,
NY). Plates were sealed and stored at 80°C for later RNA isolation/
cDNA synthesis.
MPER-specific single-B-cell cDNA generation, PCR, and cloning.
Ourmethod for cloning and expression of mouse immunoglobulin genes
from single B cells was adopted from themethod developed by Tiller et al.
(53) and utilized the primers and vectors they described. In brief, 96-well
plates with single B cells were thawed on ice, and 5l of reverse transcrip-
tion primer mix (1 l random primers, 1 l deoxynucleoside triphos-
phates [dNTPs] [10mM concentration of each], 1 pmol [each] 1st-round
PCR reverse heavy and kappa light chain [IgH and IgLk] primers, and
DNase/RNase-free water) was added to each well. The plate was heated to
65°C for 5 min in a thermocycler and then cooled on ice for 1 min.
SuperScript3 reverse transcription mix containing 5 reverse transcrip-
tion buffer, dithiothreitol (DTT), RNase Out, SuperScript3, and DNase/
RNase-free water was added to a final volume of 30l, and cDNA synthe-
sis was performed by running the following ramped thermocycler
program: 25°C for 5 min, 50°C for 60 min, 55°C for 60 min, and 70°C for
15 min. A nested PCR strategy was used to amplify the IgH or IgLk im-
munoglobulin gene from cDNA. First- and second-round nested PCRs
were performed using high-fidelity Q5 polymerase (New England Bio-
Labs, Ipswich, MA). For IgH amplification, 3 l of cDNA reaction mix
was added to a total of 50l of PCRmix and amplified using the following
program: 98°C for 30 s, 50 cycles of 98°C for 30 s, 50°C for 30 s, and 72°C
for 30 s, and a final extension at 72°C for 10 min. The same strategy was
implemented for IgLk amplification, but with a 47°C annealing tempera-
ture instead of 50°C. The second-round PCRwas performed using 1l of
the first-round template for nested amplification with the same thermo-
cycler programs as those described above. DNA sequences were obtained
using the second-round PCR 5= primermix. IgH and IgLk pairs of interest
were cloned by determining the closest-matching V-gene/J-gene cloning
primer sets described by Tiller et al. and reamplifying the sequence from
the first-round PCR product. The resulting fragment was gel purified,
inserted into the pCR-BLUNT II TOPO vector by use of topoisomerase I
(Zero Blunt TOPO cloning kit; Thermo Fisher, Waltham, MA), and
transfected into Escherichia coli for subcloning (One-Shot TOP10 chem-
ically competent cells; Thermo Fisher, Waltham, MA). Plasmids were
isolated, sequenced to confirm fidelity, and restriction digested for inser-
tion into the IgH and IgLk expression vectors for human IgG1 and kappa
chain, respectively. Expression of rMAbs was performed by transfecting
30-ml cultures of exponential-growth-phase 293F cells with 20g each of
IgH and IgLk in their respective vectors by use of 293Fectin (Thermo
Fisher,Waltham,MA)with shaking in a cell culture incubator at 37°C and
5% CO2 for 7 days. Expressed rMAbs were isolated by pelleting cells,
filtering the supernatants to 0.22 m, purifying immunoglobulin by use
of Gamma-bind Plus Sepharose beads (GE Healthcare, Little Chalfont,
United Kingdom), and concentrating the samples with 30K centrifugal
filters.
MPER/liposome and cardiolipin/dsDNA ELISAs. Enzyme-linked
immunosorbent assays (ELISAs) for measuring MPER-specific antibod-
ies from sera were done by labeling Immulon 1B plates overnight with 2
g/ml streptavidin in PBS (50 l/well) at 4°C. The following day, plates
were washed three times with 0.1% BSA-PBS and blocked with 100l per
well 1%BSA-PBS for 3 h. Incubationwith 0.2% biotinylated polyethylene
glycol (PEG) 2000-containing Npalm-MPER-NH2/liposomes or Npalm-
MPER-COOH/liposomes (1:50 peptide:lipid ratio) at 32 g/ml in 1%
BSA-PBS was then carried out for 2 h with shaking at room temperature
and then for another 2 h at 4°C. Plateswere thenwashed again, and serially
diluted sera in 1% BSA-PBS were aliquoted and incubated overnight with
gentle rocking at 4°C. The following day, serum samples were removed,
the plate was washed, and goat anti-mouse–horseradish peroxidase
(HRP) secondary antibody (Bio-Rad, Hercules, CA) at a 1:2,000 dilution
was applied for 1 h at 4°C. Plates were washed two times with 0.1% BSA-
PBS and two times with PBS. Bound antibody was detected by incubation
with o-phenylenediamine (OPD) solution in citrate buffer, pH 4.5, for 10
min. The OPD reaction was stopped with 2.25 M H2SO4, and the absor-
bance was read at 490 nm on a Victor X4 plate reader (Perkin-Elmer,
Waltham, MA). Autoreactivity/polyreactivity of MPER-specific rMAbs
was tested by ELISAs with cardiolipin and double-stranded DNA
(dsDNA) by coating Immulon 2HB plates (Thermo Scientific, Waltham,
MA)with 75g/ml cardiolipin (Sigma-Aldrich, St. Louis,MO) in ethanol
and allowing them to air dry overnight or coating themwith 100g/ml of
sheared 0.45-m-filtered salmon sperm DNA (Life Technologies, Grand
Island, NY) in PBS overnight at 4°C. Plates were washed three times with
0.05%Tween 20-PBS, and all wells were blockedwith 1%BSA-PBS for 1 h
at room temperature with shaking. Plates were washed with 0.05%Tween
20-PBS, and serially diluted rMAbs were incubated for 1 h at room tem-
perature. Washing was repeated, and the wells were incubated with
1:3,000 goat anti-human IgG–HRP (Bio-Rad, Hercules, CA) antibody for
1 h at room temperature. Plates were washed six times with 0.05% Tween
20-PBS, and bound antibody was detected using OPD solution as de-
scribed above. Non-antigen-coated plates were set up in parallel to mea-
sure nonspecific binding and to subtract the background signal from the
total.
ELISPOTquantificationofMPER-specificASCs.Enzyme-linked im-
munosorbent spot (ELISPOT) analysis for quantifying the numbers of
antigen-specific antibody-secreting cells (ASCs) from BM, spleens, and
lymph nodes was performed using 96-well 0.45-m, hydrophobic, high-
protein-binding Immobilon-P polyvinylidene difluoride (PVDF) mem-
brane plates (EMD Millipore, Billerica, MA). Plates were activated with
35% ethanol and then washed eight times with water, followed by incu-
bationwith 100l per well of various 100-g/mlNpalm-MPER/liposome
formulations in PBS (1:50 or 1:1,000MPER:lipid ratio; 4:1 DOPC:DOPG
ratio) overnight at 4°C. Plates were washed six times with 0.1% BSA-PBS,
blocked with 200 l/well 1% BSA-PBS for at least 4 h, washed once with
RPMI 1640 medium supplemented with 10% FBS, glutamine, 2-mercap-
toethanol, and penicillin-streptomycin, and then blocked for 1 h at 37°C
with the samemedium.Meanwhile,mouse spleens, inguinal lymph nodes
(iLN), and BMwere isolated, and single-cell suspensionswere prepared in
the aforementioned growthmedium. Cells were strained to 70m, quan-
tified using a hemacytometer, and resuspended to 1  107 cells/ml. The
growth medium block was removed from plates and replaced with 50
l/well fresh growth medium. Cell suspensions were restrained to 70 m
and added to wells in 50-l volumes (500,000 cells), in triplicate or qua-
druplicate. Hybridoma cells (M1) which secrete a C-terminalMPER-spe-
cific antibody and BNAb 2F5-expressing cells were plated as controls.
Cells were incubated overnight at 37°C and 5% CO2 in a humidified
chamber. The following day, wells were washed six times with 0.1% BSA-
PBS and blocked for 1.5 h with 1% BSA-PBS. The blocking buffer was
discarded, and bound antibody was detected using 0.6 g/ml of alkaline
phosphatase (AP)-conjugated goat anti-mouse secondary antibodies
rMAbs from LLPC Induced by MPER/Liposome Immunization
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(anti-IgM, anti-IgG1, anti-IgG2a, anti-IgG2b, anti-IgG3, and anti-IgG;
Jackson ImmunoResearch, West Grove, PA) in 1% BSA-PBS. BNAb 2F5-
secreting control cells were visualized using goat anti-human IgG–AP. To
visualize MPER-specific bound antibody, wells were washed eight times,
and 100 l/well 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetra-
zolium (BCIP/NBT) solution was added for 5 min. Plates were washed
thoroughlywith distilledwater and dried overnight. Spotswere quantified
using a CTL ImmunoSpot ELISPOT plate reader and ImmunoSpot 3
software (CTL, Shaker Heights, OH).
SPR analysis. Surface plasmon resonance (SPR) analysis was done as
described previously (42). Briefly, for alanine scanning analysis, 30 l of
150 M-250 M DOPC-DOPG liposomes in running buffer (20 mM
HEPES, 0.15mMNaCl, pH 7.4) was applied to a Pioneer L1 sensor chip in
a BIAcore 3000 instrument at a flow rate of 3l/min at 25°C.Multilamel-
lar structures were removed by injection of 20 l of 25 mM sodium hy-
droxide at a flow rate of 100 l/min. MPER peptides (0.5 M) were
dissolved in running buffer right before injection and complexed with the
liposomes by injection of 60l at a flow rate of 10l/min. Binding ofMAb
was then tested by passage of theMAbover the peptide-liposome complex
at 10 l/min. Peptide-liposome complexes were removed by sequential
passages of 40 mM 3-[(3-cholamidopropyl)-dimethylammonio]-1-pro-
panesulfonate (CHAPS) and 3:2 sodium hydroxide (50 mM)-isopropyl
alcohol over the sensor chip. For liposome-only or MPER/liposome
rMAb binding analysis, 30 l of each purified rMAb at 30 g/ml was
applied to the chip at a flow rate of 10 l/min for 3 min, using a protocol
identical to that for alanine scanning analysis (42).
Immunoglobulin gene sequence analysis. Immunoglobulin genes
from two mice (n  66 total sequences generated) were amplified from
single MPER-specific IgG-secreting plasma cells. The sequences were
aligned by use of IMGT/HighV-QUEST (version 1.5.1) to identify their
V(D)J germ line segments. Sequences for which a junction could not be
identified (n  18) were excluded from further analyses, leaving 15 se-
quences formouse 1 and 33 formouse 2 for detailed investigation. Down-
stream analyses were performed using tools from the Change-O suite
(version 0.3.3-2016.04.22) and the associated R packages SHazaM
(shazam_0.1.2.999) and alakazam (alakazam_0.2.3.999) (54). Detailed
information is available at http://immcantation.readthedocs.io. Se-
quenceswere assigned to the same clonewhen they shared the same IGHV
gene, IGHJ gene, IGLkV gene, IGLkJ gene, and junction length, with a
Hamming distance threshold of 0.05, using the DefineClones command
line tool. For each clone, the germ line sequences were identified for the
heavy and light chains by use of the CreateGermlines tool, and the germ
line definitions were retrieved from IMGT (as of 2 May 2016). SHazaM
was used to quantify themutation frequencies for the V segment up to the
start of CDR3 by comparison to the IMGT germ line gene segment, and
also broken down by region (complementarity-determining region
[CDR], framework region [FWR], or entire sequence). BASELINe (ver-
sion 1.3 [30 January 2014]) (55) was used to quantify selection strength in
the CDR and FWR by using the Focused test statistic and the mouse
trinucleotide SHM targeting model and selecting the clonal sequence op-
tion.
MPER constructs.MPERpeptides were generated on anABI 431 pep-
tide synthesizer by using Fmoc chemistry, high-pressure liquid chroma-
tography (HPLC) purification, and postpurification conjugation of N-
terminal palmitic acid at the Massachusetts Institute of Technology, as
described previously (42). Peptide amino acid sequences were as fol-
lows: MPER-NH2, palm-ELDKWASLWNWFNITNWLWYIK-NH2;
MPER-COOH, palm-ELDKWASLWNWFNITNWLWYIK-COOH; W680A-
COOH, palm-ELDKWASLWNWFNITNWLAYIK-COOH; MPER-N,
palm-GSGSDLLELDKWASLWNWFNIT-NH2; and MPER-C, palm-
GGGSSASLWNWFNITNWLWYIK-NH2.
RESULTS
MPER/liposome immunizations generate antigen-specific LLPC.
Circulating high-affinity antibodies are maintained for decades
by LLPC without reexposure to antigen, providing protection
against previously encountered pathogens (56, 57). Therefore, an
effective antibody-based vaccine must stimulate production of
antigen-specific LLPC. We tested the ability of the MPER/lipo-
some formulation to generate LLPC and characterized this popu-
lation at the single-cell level. To this end, BALB/c mice were im-
munized three times at 21-day intervals with the MPER anchored
to the liposome membrane via a covalently attached N-terminal
palmitoyl adduct. The liposomes were previously optimized (41,
42) to trigger humoral responses by including the Toll-like recep-
tor 4 (TLR4) agonistMPLA as an adjuvant and the I-Ad-presented
T cell epitope LACK1, the immunodominant peptide of the Leish-
mania major LACK protein, to stimulate CD4 T cell help (58).
Following immunization, sera were drawn from mice and end-
point titers for IgG isotype antibody binding to MPER/liposomes
determined by direct ELISA. ELISA revealed that MPER-specific
antibody endpoint titers of approximately 80,000 were main-
tained for up to 180 days following the third immunization (Fig.
1A). Since we previously showed that MPER/liposome immuni-
zations result in dominant antibody responses directed to the C-
terminal helix of the MPER, including the free amide exposed on
the C-terminal end of the MPER sequence following synthesis
(K683) (42), we also determined the magnitude of the serum an-
tibody responses independent of the free amide in binding speci-
ficity by using MPER-COOH peptides. The analysis revealed that
non-amide-reactive MPER-specific serum antibody responses
were durably maintained by LLPC as well, albeit at 8 times lower
titers.
Next, we determined the frequency of ASCs in BM over time
following the third immunization. By coating 96-well PVDF
membrane plates withMPER/liposomes and then incubating BM
cells on the membranes overnight, the ASCs were visualized and
quantified by ELISPOT assay, analogously to the procedures em-
ployed for soluble protein antigens. Consistent with the serum
endpoint titer results, the majority of MPER-specific ASCs (50/
106 cells to 100/106 cells) were of the switched IgG isotype, partic-
ularly IgG1; however,10 MPER-specific ASCs/106 cells of each
of the IgM, IgG2a, IgG2b, and IgG3 isotypes were alsomaintained
for up to 180 days (Fig. 1B). The same trend was also observed
with MPER-specific BM plasma cells after the second immuniza-
tion (data not shown). To assess the relative affinities of antibodies
produced by ASCs in BM for the MPER following the third im-
munization, we developed a simple assay based on ligand display.
We reasoned that a low-affinity antibody would not bind to
MPER/liposomes in which theMPER was presented at a low den-
sity (1:1,000 peptide:lipid ratio) versus the higher density (1:50
ratio) used for total ASC quantification. The use of lower-density
MPER in the liposome array (1:1,000 ratio) to exclusively detect
high-affinity antibodies was validated by control experiments us-
ing representative high- and low-affinity rMAbs (113 and 196,
respectively) elicited by MPER/liposome immunization and by
comparison with the high-affinity 2F5 and 4E10 BNAbs (Fig. 1C).
In addition, as shown subsequently, the relative binding affinities
of rMAbs 113 and 196 were 3,400 response units (RU) and 380
RU, respectively, forMPER/liposomes at 30g/ml asmeasured by
surface plasmon resonance (SPR) (see Fig. 4A). Parallel analysis at
various MPER:lipid density ratios (1:50 to 1:1,000) by ELISA re-
vealed that 2F5, 4E10, and the high-affinity clone 113 bound well.
In contrast, the low-affinity clone 196 antibody bound to MPER/
liposomes at the 1:50 ratio with a high signal but had little reac-
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tivity to those at ratios at or below 1:250 (Fig. 1C). Quantification
of the numbers of cells binding the MPER/liposomes at 1:1,000
(low ratio) versus the high ratio (1:50) by ELISPOT analysis re-
vealed that the percentage of cells binding both MPER/liposomes
at 1:1,000 and MPER/liposomes at 1:50 reached and was main-
tained at nearly 60% by 60 days after the third immunization (Fig.
1D). These analyses indicate that the MPER-specific IgG-produc-
ing LLPC in BM are associated with the persistent MPER-specific
antibody responses in serum. Moreover, not all MPER-specific
LLPC in BM produce high-affinity Abs (e.g., rMAb clone 196 has
a low affinity) (Fig. 1C).
Isolation of single MPER-specific LLPC by microengraving.
Wenext sought to characterize the variable (V), diversity (D), and
joining (J) gene segments of immunoglobulins elicited by MPER/
liposomes by using DNA sequencing at the single-cell level. This
approach allowed us to determine the diversity of B cells recruited
FIG 1 MPER/liposome immunization results in long-term, MPER-specific, isotype-switched antibody responses. (A) Endpoint titers of MPER-NH2/liposome
(circles)- andMPER-COOH/liposome (squares)-specific IgGs were measured by ELISA at the indicated time points after the third immunization. Control data
from naive mice are shown with blue circles (anti-MPER-NH2/liposomes) and squares (anti-MPER-COOH/liposomes). (B) Kinetics of MPER-binding and
isotype-specific ASCs elicited after the third immunization. Numbers ofMPER-binding ASCs from BMwere determined by ELISPOT assay, usingMPER-NH2/
liposomes as the capture antigen. Quantification of numbers of anti-MPER-specific ASCs per 106 bone marrow cells was performed by ELISPOT assay at the
indicated time points. Secretion of immunoglobulin was assessed by specific isotype. Symbol colors: black, IgG; blue, IgG1; orange, IgM; pink, IgG3; purple,
IG2b; red, IgG2a. (C) Low-affinity (196) but not high-affinity (113) rMAbs are sensitive to the copy number of MPER segments arrayed on the surface of a
liposome. ELISA plates coated with streptavidin were incubated with liposomes containing biotin-PEG 2000 as well asMPER at peptide:lipid ratios of 1:50 (red),
1:250 (green), 1:500 (blue), and 1:1,000 (purple) or with bare liposomes (black). All serially diluted Abs (from 2g/ml to 64 pg/ml) were incubated on liposomes
overnight and developed with anti-human secondary antibody. Points shown represent means for duplicate analyses. High-affinity BNAbs 2F5 and 4E10 were
compared as positive controls, and irrelevant rMAb 229 was used as a negative control. (D) Relative affinities of MPER-binding IgG BM ASCs at different time
points as assessed by ELISPOT assay. The frequencies of low-density MPER/liposome (1:1,000 [mol:mol])- and high-density MPER/liposome (1:50)-binding
IgGASCs were determined, and the ratios of low-densityMPER (1:1,000) to high-densityMPER (1:50) binding were plotted. All points in panels A, B, andD are
means standard errors of the means (SEM) for quantification of data from 3 independent mice at each time point for ELISA and ELISPOT assays. Represen-
tative data are shown. All graphs represent BALB/c mice immunized with Npalm-MPER/liposomes loaded with a LACK1 T cell helper peptide andMPLA as an
adjuvant, administered by intradermal injections on three occasions at 3-week intervals.
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as components of the anti-MPER response by the extent to which
these cells underwent somatic hypermutation (SHM) and then
through recombinant protein expression to define the molecular
characteristics, including CDR3 lengths, important for MPER
binding. To identify and isolate MPER-specific LLPC, we took
advantage of the versatile microengraving technology, which uses
a dense array ofmicrowells (0.1 to 1 nl each) containing individual
cells to print a corresponding array of antibodies secreted by each
cell (59, 60). Microengraving is performed by distributing cells on
an injectionmold containing grids ofmicrowells and exposing the
wells to an antigen-coated slide. In detail, plasma cells were puri-
fied from mouse BM cells 10 days after the third immunization
with various MPER/liposome formulations, resuspended in me-
dium containing human IL-6 to mark the grid, and distributed
onto an array of microwells in a poly(dimethylsiloxane)-injected
mold to allow the analysis of 100,000 total cells per array (Fig.
2A). A glass slide coated with MPER/liposomes (1:50 MPER:lipid
ratio) and anti-human IL-6 was placed over the wells. The slide-
mold arrangement was clamped into position and incubated for
1 h to allow secreted antibodies to bind toMPER/liposomes, while
the IL-6 was bound by the coprinted anti-IL-6 capture antibody
(Fig. 2B).M1 hybridoma cells producingMPER-specific antibody
were tested as a positive control to demonstrate the lucidity of the
method for localizing wells with MPER-specific cells (Fig. 2C, left
panel). After incubation, the slide was removed, and Alexa 488-
labeled anti-IL-6 was used to visualize the grid of the mold (Fig.
2C, middle panel, yellow wells). The MPER-specific antibody
was detected with Alexa 647-labeled anti-mouse IgG, and this
signal (shown in green) was overlaid on the IL-6 signal so that
wells containing MPER-specific cells could be located (Fig. 2C,
right panel). The cells were binned by their supernatants’
MPER antibody detection signal intensities (Fig. 2D) and were
retrieved by use of a micromanipulator for reverse transcrip-
tion-PCR (RT-PCR).
The frequencies of MPER-specific plasma cells in BM 10 days
after the third immunization with Npalm-MPER/liposomes
FIG 2 Identification and isolation of single MPER-specific BM plasma cells by use of microengraving technology. (A) Diagram of the microengraving method.
(B) Interrogation of slides after printing. MPER-specific Abs captured on MPER/liposome-coated slides were detected with Alexa 647-conjugated anti-mouse
IgG.Human IL-6 was detected with Alexa 488-conjugated anti-human IL-6 to produce signals in every well for grid alignment and localization ofMPER-specific
signals. Human IL-6 was added to the printing medium. (C) Establishment of the microengraving system by using MPER-specific M1 hybridoma cells. The
MPER-specific signals (green squares) were overlaid on the IL-6 signals (yellow squares) for localization of MPER-specific cells and retrieval for analysis. The
MPER-specificM1 hybridoma cell line was used as an example. (D) Detection ofMPER-specific plasma cells from bonemarrow. Plasma cells were isolated from
BMbydepleting B220 cells andCD49b cells and then enriching forCD138 cells. A total of 2,674MPER-specific signals were detected from70,000BMplasma
cells isolated from one mouse immunized with Npalm-MPER/liposomes, whereas only 11 signals, all with signal intensities of	5,000, were detected from an
unimmunized mouse.
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ranged from1.5 to 3% of total plasma cells by microengraving;
the results of one representative experiment are shown in Fig. 2D.
Only 10 to 20 cells from an immunologically naive mouse were
scored positive, but with signal intensities of	5,000 (Fig. 2D).
Genetic characterization of MPER-specific Ig repertoires.
BNAbs to HIV have been typified by long CDRH3 sequences and
high mutation frequencies (6, 61), with the antibody responses to
some epitopes dominated by particular VH genes, such as the
well-defined prevalence of VH1-2 among the CD4-binding site
agonist antibodies (62–65). To investigate the genetic composi-
tion of the MPER-specific Ig repertoires, RT-PCR was utilized to
amplify variable regions of naturally paired IgH and IgLk antibod-
ies by using a strategy previously described by Tiller et al. (53).
Immunoglobulin genes from two mice immunized with Npalm-
MPER/liposomes were amplified from singleMPER-specific IgG-
secreting plasma cells. The sequences (n 66 total sequences gen-
erated) were aligned by use of IMGT/HighV-QUEST (version
1.5.1) to identify their V(D)J germ line segments. Sequences for
which a junction could not be identified (n 18) were excluded
from further analyses, leaving 15 sequences formouse 1 and 33 for
mouse 2. The MPER-specific immunoglobulin repertoires were
derived from a diverse collection of gene families for both the VH
(IgH V gene) (Fig. 3A) and VL (IgLk V gene) regions (Fig. 3B),
some of which were clonally expanded. As shown in Fig. 3C, the
sequences also used a diverse set of CDRH3 lengths, which fell
within the range of expected lengths for mice. Virtually all of the
sequences (94%) showed somatic hypermutation, with averages
of 2.9 and 1.7 mutations/100 bases for VH and VL, respectively,
and with a higher frequency of mutations in the CDRs (Fig. 3D).
To determine whether these mutation patterns were driven by
affinity maturation, we quantified selection strength (
) by using
the BASELINe method (55). Positive values for 
 reflect a higher
incidence of nonsynonymous mutations than expected and are
associated with positive selective pressure, while negative values
for 
 reflect a higher incidence of synonymous mutations than
expected and are associated with negative selection pressure.
BASELINe analysis revealed significant evidence for positive selec-
tion in the CDR, as expected for antigen-driven affinity matura-
tion (
  0.59; P  0.005). In addition, there was significant
negative selection in the framework regions (FWR), as expected to
preserve the overall antibody structure (
  0.62; P  0.015)
(Fig. 3E). Thus, the MPER-specific Ig repertoires reflect a diverse,
affinity-matured cell population.
Residue-specific binding analysis of rMAbs reveals common
epitope recognition with diverse functional characteristics.We
next selected a representative group of matched IgH/IgLk se-
quences that included CDRH3 lengths across the range of 5 to 19
amino acids and sequences representing diverse gene families. A
total of 20 rMAb clones were selected for expression and charac-
terization by cloning of the selected amplicons into IgH/IgLk ex-
FIG 3 Immunoglobulin gene usage within the MPER-specific bone marrow plasma cell population is diverse. Immunoglobulin genes from two mice (n 66 total
sequences generated; 48 sequences were analyzed) were amplified from singleMPER-specific IgG-secreting plasma cells. The usage frequencies of immunoglobulin VH
genes (IGHV)(A)andVLgenes (IGKV)(B)arediverse.Vgene familiesweredefinedusing IMGTandcolor codedbygene family.Thenumberof sequences representing
each IGHV and IGKV family is shown, with horizontal gray lines separating groups of clonally related sequences within each V gene cohort. (C) Box plot of CDRH3
length distributions. CDRH3 regions were identified by IMGT, and amino acid lengths were calculated. Each point represents a sequence from mouse 1 (circles) or
mouse 2 (triangles). For comparison,mouseCDRH3 lengths for IgG sequences from splenocytes or plasmablasts (PB) are shown, using previously published data (76).
Note that a single outlier point formouse splenocytes is not shown.Themeanvalue for eachgroup ismarkedwith a cross. (D)Thenumberof somaticmutationsper 100
germ line-definedbasepairswas calculated for theCDRs, theFWRs, and the entire sequenceof the IgH(gray columns) and IgLk (black columns)Vgenes. (E)BASELINe
analysis of selection pressure on IgHVgene sequences. Significant positive selectionwas calculated for nonsynonymousCDRmutations (
 0.59;P 0.005; red line),
along with significant negative selection against nonsynonymous mutations in the FWR region (
  0.62; P  0.015; blue line). The data represent analyses of
sequences from two independent B cell/immunoglobulin gene isolations bymicroengraving.
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pression vectors as described previously (53). The purified rMAbs
were then confirmed to have MPER specificity by SPR analysis.
Figure 4A and B show relative binding affinities of 20 rMAbs for
the MPER arrayed on the surfaces of MPER/liposomes and for
liposomes alone. Although LLPC are high-affinity antibody pro-
ducers, not all MPER-specific rMAbs appear to be high affinity by
qualitative measures, as exemplified in Fig. 4A and 1C.While sev-
eral antibodies showed modest binding reactivity to liposomes
alone, the majority of rMAbs had no or weak lipid binding, with
no direct correlation to the affinity of the Abs for MPER.
To determine the fine epitope specificity of the rMAbs, we
performed SPR binding analysis using a panel of single alanine
mutants comprising each of the 22MPER amino acids. Given that
an amide group at the C terminus of the MPER was critical for
antibody binding in polyclonal immune sera (42), an MPER-
COOH construct was also included to evaluate the binding con-
tribution of the amide. The binding reactivities of all 20 purified
rMAbs were reduced by MPER-COOHmutation, indicating that
all rMAbs recognized the C-terminal helix of theMPER. Based on
the hierarchy of relative binding affinities (Fig. 4A) and the genetic
usage of the 20 rMAbs tested, further fine epitope mapping was
performed on a collection of 12 rMAbs. As shown in Fig. 5A for
the representative set of 12 rMAbs, a conserved antibody binding
footprint was observed, requiring S668, N677, W680, and the C-
terminal amide in MPER. However, for W672, F673, N674, I675,
and L679, each specific residue’s contribution to binding differed
somewhat between antibodies. Overall, the rMAbs showed fine
epitope specificities similar to but distinct from those of 4E10 and
10E8 (6, 12). In addition,with the exception of clones 599 and 646,
VH and VL gene usages suggested that all were derived from dif-
ferent germ line B cell lineages with different CDRH3 lengths,
ranging from 8 to 15 residues (Fig. 5B), demonstrating that a
surprising amount of gene diversity can lead to a conservedMPER
epitope specificity.
As an orthogonal approach, we screened the ASCs for epitope
specificity by ELISPOT assay. Besides the MPER-COOH mutant
noted above, we designed a second amide-lacking variant with a
W680A mutation (W680A-COOH). Further, we included two
truncated MPER peptides. One, termed MPER-N, contained the
amino acids fromE662 to T676, and the second, termedMPER-C,
included amino acidsA667 toK683, comprising the nominal 10E8
binding site. All five of these peptides were N-terminally palmi-
toylated for ease of incorporation into liposomes. We arrayed
them on liposomes and screened ASCs from BM, inguinal lymph
nodes (iLN), and spleens for reactivity 5 days after the initial
booster immunization with Npalm-MPER/liposomes (Fig. 5C).
TheMPER-NH2 variant, which was the immunogen, represented
the most frequent ASC specificity (50 iLN, 100 spleen, and
75 BM ASCs/106 cells) (Fig. 5C). On the other hand, MPER-
COOH and W680A-COOH captured antibodies from ASCs at
significantly lower frequencies (5 iLN,25 spleen, and20 BM
ASCs/106 cells for MPER-COOH and 0 iLN, 25 spleen, and
10 BMASCs/106 cells for W680A-COOH). Furthermore, while
MPER-N was not bound by antibodies from ASCs in the iLN,
spleen, or BM, the MPER-C was bound. Taken together, these
results indicate that although weak, a small fraction of Abs
recognize the C-terminal region of MPER independently of the
NH2 group, and the results are consistent with the antibody
titer against MPER-COOH detected in serum (Fig. 1A).
MPER/liposome immunizations do not generate polyreac-
tivity to cardiolipin and dsDNA.MPER-specific BNAbs, such as
2F5 and 4E10, have long CDRH3 and have been found to be poly-
reactive. In addition, both the lipid-integrated nature of the
MPER and the amino acid sequence of the MPER shared with
some parts of autologous proteins (kynureninase and splicing fac-
tor 3B subunit 3) have been proposed to make the MPER stealthy
to all but nonpolyreactive antibodies (47). Given that the MPER/
liposome-elicited rMAbs all displayed a common binding foot-
print, but with distinct genetic and biochemical properties, in-
cluding CDRH3 length (Fig. 5), we reasoned that if polyreactivity
were the characteristic of MPER-specific Abs, many antibodies
with long CDRH3 would bind to standard model targets, such as
cardiolipin and/or dsDNA. In addition to the 20 rMAbs generated
with the Npalm-MPER immunogen, another 22 rMAbs, gener-
ated from MPER mutant Npalm-W680A/liposome and MPER-
Cpalm/liposome (MPER palmitoylated at the C terminus) immu-
nizations, were also tested for cardiolipin and dsDNA reactivity
and compared with 2F5, 4E10, and 10E8. Notably, most antibod-
ies (39/44 rMAbs) tested did not bind either cardiolipin or dsDNA
(Fig. 6A), including three rMAbs elicited with the MPER mutant
Npalm-W680A/liposome immunization, which exhibited 2F5-
like epitope specificity. Among the 20 rMAbs characterized in Fig.
4 and 5, four antibodies (198, 207, 219, and 193) were polyreac-
tive. The epitope specificities of antibodies 198 and 230 were dis-
tinct but were most similar to that of 10E8 (Fig. 5A), with only
FIG 4 Binding specificities of rMAbs analyzed by SPR analysis. Results are
shown for 20 rMAbs binding to MPER/liposomes (DOPC/DOPG) (A) and to
liposomes only (B). The scale bars have been equalized to demonstrate the
clear specificity for the MPER. Each purified rMAb was tested at 30 g/ml by
injection over L1 chip-bound MPER/liposomes or liposomes only at a flow
rate of 10 l/min for 3 min.
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antibody 198 manifesting cardiolipin binding. The rMAbs 198
and 207 bound cardiolipin similarly to the BNAb 2F5 but half as
well as antibodies 650 and 219 at 5g/ml. Antibodies 650 and 219
also bound dsDNA at concentrations down to 0.1 g/ml and 1
g/ml, respectively, while rMAb 193 joined them, with dsDNA
sensitivity at concentrations down to 1 g/ml. All five of these
rMAbs recognized the C-terminal helix of MPER. The five anti-
bodies that showed polyreactivity (650, 219, 198, 207, and 193)
had CDRH3 lengths ranging from 5 to 14 residues. Although a
long CDRH3 loop has been associated with polyreactivity (66), no
correlation between polyreactivity and the length of the CDRH3
loop was observed in this study (Fig. 6B).
The CDRH3 loops ofMPER-specific antibodies reveal disso-
ciable antigen specificity and polyspecificity properties. To fur-
ther define the dual reactivity ofMPER-specific Abs, we evaluated
the biochemical properties of the antigen combining sites of two
different sets of antibodies. Clones 198 and 252 shared the same
VH gene and JH gene segments (HV12-1/HJ4) and IgLk VL gene
usage (KV4-53) but differed in their JL gene usage (KJ4 versus KJ5,
respectively) (Fig. 7A). These clones utilized different D gene seg-
ments, resulting in very different CDRH3 sequences (SREKN-
WEMDY for clone 198 and SRENPKIYYALDY for clone 252).
Interestingly, the binding properties of these two clones also var-
ied significantly. Clone 252 boundMPER/liposomeswith a higher
on-rate and a higher overall response than those of clone 198 by
SPR analysis (Fig. 7B), but by ELISA, clone 198 bound the lipid
cardiolipin, while clone 252 binding was barely detected (Fig. 7C).
Therefore, clone 198 reactivity manifested both MPER-specific
FIG 5 rMAb epitope mapping analysis reveals convergence to a common epitope at the C-terminal region of theMPER and use of various CDRH3 lengths. (A)
Epitope specificity analysis by BIAcore of 12 representative rMAbs by use of liposome-bound serial single alanine MPER mutants. The y axis shows the percent
relative binding activities of Abs against each single-residue mutant compared to that of wild-type MPER (WT) (100%). Colored lines represent the epitope
specificities of MPER/liposome immunization-derived antibodies, and bars represent the BNAb 10E8. (B) IgH (blue table) and IgLk (green table) V(D)J gene
usage and CDR3 analysis of the 12 representative rMAbs from panel A. The germ line gene segment usage, CDR3 lengths, and sequences of the MPER-specific
Abs were determined via IMGT/HighV-QUEST analysis. (C) Frequencies of MPER-specific ASCs with different specificities in various organs 5 days after the
second immunization with Npalm-MPER/liposomes. Numbers of MPER-binding ASCs were determined by ELISPOT assay, using each of the different
epitope-specific MPER/liposomes as the capture antigen. MPER-NH2 and MPER-COOH indicate the HXB2 MPER with C-terminal NH2 and COOH ends,
respectively, and W680A-COOH indicates a W680 mutation to A with a C-terminal COOH. The MPER-N (E662 to T676) and MPER-C (A667 to K683)
sequences are indicated in panel A.
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reactivity and polyreactivity, while clone 252 was MPER specific
and lacked polyreactivity (Fig. 6A and 7C). The DOPC/DOPG
liposome binding of both clones 198 and 252 was weak (Fig. 7B,
right panel), and this trend was supported by negligible reactivity
of either clone to dsDNA (Fig. 7C). As shown in Fig. 7B (left
panel), when the IgH of clone 252 was paired with the IgLk of
clone 198 (252H/198K chimera), binding to MPER was dramati-
cally reduced, with only30% residual binding reactivity relative
to that of the clone 252 parent IgGpair. Similar results were shown
with 198H/252K chimera binding to the MPER relative to that of
clone 198. Next, the chimeric rMAb 252Mwas made by swapping
the CDRH3 of clone 252 with that of clone 198 to determine the
critical role of CDRH3 for antigen specificity. Swapping of the
CDRH3 of clone 198 with that of clone 252 resulted in the abro-
gation of 252M binding to MPER/liposomes as determined by
SPR analysis (Fig. 7B, middle panel). On the other hand, 252M
bound cardiolipin with 3 times the absorbance of its parent
CDRH3-containing rMAb 198 and with 10 times the absorbance
of clone 252 at a concentration of 5 g/ml (Fig. 7C). Similar to
clones 198 and 252, the chimeric Ab 252M did not have dsDNA
reactivity (Fig. 7C). Note that nonspecific liposome binding
(DOPC/DOPG) of 252M was also increased compared to that of
clones 252 and 198 (Fig. 7B, right panel). As shown in Fig. 8A, the
sequences of clone 252 IgL and clone 198 IgL differ by 5 amino
acid residues. Two of these residues are relatively homologous,
i.e., M94 (clone 252)/V94 (clone 198) in the FR3 region and L112/
V112 near the end of the CDRL3 loop, and probably have little
effect on MPER binding. H38/N38 is in the CDRL1 loop, which
may contact theMPER, andL40/H40 in FR2 is buried but adjacent
to the CDRH3 loop (Fig. 8B). It is possible that these two residues
influence the conformation of the CDRH3 loop, resulting in the
reducedMPER binding observed with the 198H/252K and 252H/
198K chimeras (Fig. 7B, right panel). The fifth residue, N66/K66,
located at the beginning of the FR3 region, is also in the vicinity of
the CDRH3 loop and may play a minor role. The CDRH3 loop in
clone 198 contains a tryptophan residue at its apex that confers
bettermembrane binding than that with theCDRH3 loop in clone
252. Interestingly, membrane binding of 252M increased signifi-
cantly even compared to that of wild-type clone 198, which has the
same CDRH3 loop (Fig. 7B, right panel). It is possible that the
identical CDRH3 loops in these two constructs adopt different
conformations as a result of neighboring residues or that the ap-
proach angles of the antibodies with respect to the membrane are
different. Notwithstanding this possibility, membrane binding
and cardiolipin binding were uncorrelated with MPER binding
for the wild-type clones 198 and 252 and the CDRH3 loop-
swapped mutant 252M.
In a second set of clones, 196 and 219, a trend toward a reverse
correlation between MPER binding and polyreactivity was deter-
mined by chain swap and/or CDRH3 mutations in the antibody
combining site. Clones 196 and 219 share the same VL/JL gene
pairings (KV3-1/KJ1) and have different VH/JH gene pairings
(HV5-6-5/HJ3 and HV5-6-5/HJ4) (Fig. 9A), and they differ by 13
IgH and 5 IgLk amino acids. As shown in Fig. 9B, mispairing of
IgH and IgLk of clone 196 with those of clone 219 reducedMPER/
liposome binding compared to that of clone 196 (left panel). Re-
placement of clone 219 CDRH3 with that of clone 196 to create a
new clone, 219M, greatly increased the MPER/liposome on-rate
and total binding (Fig. 9B,middle panel). However, this enhanced
MPER/liposome binding was almost entirely due to a nonspecific
lipid binding contribution (Fig. 9B, right panel). Along with in-
creased cardiolipin and dsDNA binding by 219M (Fig. 9C), these
results suggest that the 196 and 219 antibodies affinity matured
toward MPER specificity independently of polyreactivity.
FIG 6 Low frequencies of autoreactivity and polyreactivity of MPER-specific Abs elicited by immunization with various MPER/liposome vaccines. (A) Forty-four
differentMPER-specific rMAbs frommice immunizedwith liposome vaccines containingNpalm-MPER, theNpalm-W680Amutant, orCpalm-MPERwere tested for
autoreactivity and polyreactivity by cardiolipin and dsDNAELISAs andwere comparedwith anti-MPERBNAbs (red, 2F5; purple, 4E10; and green, 10E8).Data shown
are representative of three independent experiments. (B) Lack of correlation between reactivities andCDRH3 lengths among the 44 different Abs tested in panel A. The
y axis represents the absorbance at 490 nm of bound antibodies from panel A at 5g/ml, plotted against CDRH3 length on the x axis.
Donius et al.
8884 jvi.asm.org October 2016 Volume 90 Number 19Journal of Virology
 o
n
 January 24, 2017 by M
ASS INST O
F TECHNO
LO
G
Y
http://jvi.asm.org/
D
ow
nloaded from
 
DISCUSSION
Previously, we characterized the polyclonal immune serum re-
sponses of BALB/c mice elicited against an MPER/liposome vac-
cine incorporating molecular adjuvants and CD4 T cell help (41,
42). In the present study, we focused on defining the LLPC in BM
that are responsible for that serum antibody production. The im-
plementation of microengraving methods to assess MPER/lipo-
some specificity at the level of single plasma cells allowed us to
FIG 7 The CDRH3 loop plays a critical role inMPER specificity versus polyspecificity. (A) IgH and IgLk V(D)J gene usage of the related Abs 198 and 252. 252M
is a 252 variant in which CDRH3 of clone 252 was replaced by CDRH3 of clone 198. (B) Relative binding affinities of chimeric rMAbs for MPER/liposomes
compared to those ofWT clones 198 and 252 asmeasured by SPR analysis (left), binding reactivities of 252M forMPER/liposomes in comparison to those ofWT
clones 198 and 252 (middle), and lipid-binding reactivities of clones 198, 252, and 252M (right). (C) rMAbs were tested for polyreactivity by cardiolipin and
dsDNA ELISAs.
FIG 8 Comparison of rMAbs 198 and 252. (A) Amino acid residue alignments of rMAbs 198 and 252. (B) Modeling of rMAb 198 with predicted IgLk residue
differences from rMAb 252. Residues N/H38, H/L40, K/N66, V/M94, and V/L112 weremodeled on an immunoglobulin variable region ribbon structure (heavy
chain [PDB entry 1ACY] and light chain [PDB entry 5D8J], with homologous sequences). Residues V94 and V112, within FR3 and CDRL3, respectively, are
illustrated as the homologous residuesM94 and L112 in rMAb 252. Note that N38 andH40, located in CDRL1 and FR2, respectively, are adjacent to the CDRH3
and are replaced by H38 and L40 in rMAb 252. As illustrated, residue N66 at the beginning of FR3 is also near CDRL3 and is K66 in rMAb 198.
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investigate their immunoglobulin VH and VL gene usage and to
characterize representative rMAbs to elucidate the immunogenic-
ity of MPER/liposomes in finer detail. Utilizing liposome-arrayed
MPER immunogens, we observed that the majority of MPER-
specific LLPC in BM produce antibodies directed to the C-termi-
nal helix of theMPER region and exhibit evidence of affinity mat-
uration (Fig. 3, 5, and 7). These results imply that these
antibodies represent polyclonal immune responses elicited in
sera by use of Npalm-MPER/liposomes, as described previ-
ously (42). It is evident that LLPC are derived mainly from
memory B cells after booster immunization, as they are mini-
mally, if at all, detectable after primary vaccination but readily
evident, both serologically and by ELISPOT assay, following
booster immunization (Fig. 1 and 5; data not shown). B cell
repertoire analysis (Fig. 3) in conjunction with epitope map-
ping of rMAbs (Fig. 5) collectively indicated that a prominent
common epitope specificity is generated by utilization of a va-
riety of different germ line genes. This recognition of antigen
follows independent B lineage pathways through affinity mat-
uration, exploiting the structural plasticity of the antigen com-
bining site to achieve this common goal.
Antibody binding to cardiolipin, dsDNA, or Hep-2 cells is
commonly measured to assess polyreactivity or autoreactivity. As
shown in Fig. 6, only 5 of 44 MPER-specific rMAbs generated by
various MPER/liposome vaccines were polyreactive and/or auto-
reactive. No clear correlation was observed between the CDRH3
length and polyreactivity among the tested mouse MPER-specific
antibodies, nor was there an association of polyreactivity with a
particular V gene family encoding IgH or IgLk variable regions.
When CDRH3 of rMAb 252 was replaced with that of the geneti-
cally related clone 198 to create 252M, the MPER epitope speci-
ficity was abrogated. Conversely, the 252M reactivities for both
cardiolipin and dsDNAwere increased compared to those of clone
252. Note that polyreactivity of clone 198, but not clone 252, was
observed despite identical MPER epitope specificities and with
usage of the same IgH and IgLk V genes by both rMAbs. Similar
results demonstrating MPER/liposome reactivity independent of
polyreactivity were obtained with a different pair of rMAbs, 219
and 196. These data suggest a critical role of the CDRH3s of both
clones 252 and 219 in determining MPER specificity. Given that
the MPER binding affinities of the rMAbs are also affected by
interchanged pairings of IgH and IgLk, it appears that the fine
specificity of anti-MPER rMAbs requires a structural fitness of the
antibody combining site shaped by affinity maturation of B cells.
In addition, and perhaps more importantly, the results demon-
strate that not all MPER-specific antibodies are inherently poly-
specific and/or autoreactive: polyreactivity of the MPER-specific
rMAbs is separable fromantigen specificity in these examples.Our
findings are supported by a recent work characterizing a CD4-
binding-site-specific BNAb lineage over time which tracked poly-
reactivity and antigen specificity and found that precursors were
capable of obtaining and losing polyreactive characteristics inde-
pendently of their progression toward the final BNAb (67).
Whether the nonspecific liposome binding and polyreactivity in-
dependent of MPER specificity of 252M result from increased
flexibility of CDRH3 and/or hydrophobicity introduced by se-
quence changes remains to be tested. In line with these results,
increased polyspecificity was observed with alterations of the
length and hydrophobic mutations of CDRH3 of 2F5 (29). Mis-
pairings of IgH and IgL among 10E8 variants also increased poly-
reactivity (68).
The majority of the rMAbs specific for the MPER mani-
fested weak or no liposome binding (DOPC/DOPG), with only
several rMAbs showing qualitatively modest lipid binding, in-
FIG 9 Reverse correlation betweenMPER binding and polyreactivity determined by chain swap and/or CDRH3mutations. (A) IgH and IgLk V(D)J gene usage
of related Abs 196 and 219. 219M is a 219 variant in which CDRH3 of clone 219 was replaced by CDRH3 of clone 196. (B) Relative binding reactivities to
MPER/liposomes as assessed by SPR analysis of chimeric rMAbs from clones 196 and 219 compared to that of naturally paired clone 196 (left panel). Also shown
are 219M binding reactivities for MPER/liposomes (middle) and liposomes only (right) in comparison to those of WT clones 196 and 219. Thirty microliters of
each antibody at 100g/ml was injected over theMPER/liposome or liposome surface of an L1 chip at a flow rate of 10l/min for 3min. (C) rMAbs were tested
for polyreactivity by cardiolipin and dsDNA ELISAs.
Donius et al.
8886 jvi.asm.org October 2016 Volume 90 Number 19Journal of Virology
 o
n
 January 24, 2017 by M
ASS INST O
F TECHNO
LO
G
Y
http://jvi.asm.org/
D
ow
nloaded from
 
cluding clone 219 (Fig. 4 and 9). In this regard, the recent
crystal structure of 4E10 in complex with lipids showed a
CDRH1 loop interaction with the lipid head groups and a
CDRH3 loop interaction with the hydrophobic acyl chains,
emphasizing that lipids appear to be an integral component of
the 4E10 epitope (22). Given that the MPER immunogen is
embedded in the lipidmembrane, it would be interesting to test
whether the MPER-specific rMAbs we generated recognize lip-
ids differentially as part of their epitope and the extent to which
the lipid interaction observed is linked structurally to poly-
specificity as a by-product.
Elicitation of MPER-specific BNAbs has proven difficult.
Given the polyreactivity and autoreactivity of 2F5 and 4E10, it has
been suggested that immune tolerance mechanisms might limit
the elicitation of broadly neutralizing HIV-1 antibodies (47, 50).
This hypothesis was further supported by impaired B cell devel-
opment in knock-in mice expressing the 2F5 or 4E10 VHDJH and
VLJL rearrangements (69, 70). 2F5 VH-VL knock-in mice showed
profound deletion of BNAb-expressing B cells in BM at the first
tolerance checkpoint, when naive B cells begin to express surface
BCR (70). A similar finding was observed for 4E10, for which
various mechanisms of negative selection, including receptor ed-
iting, clonal deletion, and BCR downmodulation, were noted
(69). Human kynureninase and splice factor 3B subunit 3 were
identified, through a clever screening strategy, as conserved verte-
brate self-antigens recognized by 2F5 and 4E10, respectively (47).
Another screen, looking for 4E10 cross-reactivity and spanning a
library from the human proteome, did not identify the splicing
factor 3B subunit 3 autoreactivity candidate (71). Nonetheless,
further support for the 2F5-kynureninase association comes from
immunization of opossums, whose kynureninase orthologue
lacks the ELDKWA epitope, instead containing the related but
distinct ELEKWA sequence. These animals generate high anti-
body titers to the gp41 2F5 motif, in contrast to mice and other
species (47).
While it appears that the aforementioned tolerance mecha-
nisms may preclude or severely limit the generation of BNAbs
against the MPER, an increasing number of naturally infected
HIV patients produce MPER antibodies, including those with
neutralizing activity (6, 72–75). Such antibodies develop without
clinical evidence of autoimmune sequelae. Therefore, the diffi-
culty in generating BNAbs directed at the MPER via immuniza-
tion may relate primarily to issues of immunogenicity. In this
respect, our earlier work (42) revealed how immunogenicity is
dominated by residue accessibility. Sequence changes or modifi-
cations of MPER orientation relative to the membrane easily
modulate immune responses and immunodominance. Whereas
antibodies with specificity for a 2F5-like epitope were not elicited
by the Npalm-MPER/liposome vaccine, 30 to 40% of MPER-spe-
cific plasma cells were directed to the N-terminal region of the
MPER as assessed by ELISPOT assay when mice were immunized
with mutant MPER Npalm-W680A/liposomes or MPERTM/li-
posomes, the latter of which contain the transmembrane region of
gp41 (42; data not shown). Further characterization of rMAbs
generated with the mutant MPER Npalm-W680A/liposome
vaccine showed that the ELDKWA residues in the 2F5 epitope
are critical for antibody binding, including a modest binding
contribution from the K and A residues. The observation that
MPER/liposome vaccines elicited strong humoral responses in
BALB/c mice in our study but not in comparably immunized
B6 mice (45) emphasizes how strain differences in inbred mice
alter the outcome of the immune response. Our results also
highlight that the context of immunogen presentation, includ-
ing its precise three-dimensional display and sequence, plays a
critical role in humoral responses by modulating B cell selec-
tion.
The present work reveals thatMPER-specific antibodies recog-
nizing a common epitope can be generated from genetically di-
verse germ line B cells without confinement to a specific gene
usage but manifesting different functional characteristics. Some
rMAbs exhibit polyspecificity, yet the majority do not share this
feature. In keeping with our results, even though the 10E8 epitope
overlaps that of 4E10, these MAbs manifest low and high polyre-
activities/autoreactivities, respectively (51), and demonstrate dif-
ferentmodes of binding (6, 21, 22). The discovery of 10E8 strongly
implies that nonautoreactive BNAbs exist and can be elicited.
Consistent with this notion, extensive screening of the rMAb 10E8
on an array of 9,400 human proteins showed modest cross-
reactivity with only one protein, the intracellularly localized
FAM84A protein (51).
We suggest that the polyclonality of B cells responding to
the MPER peptide immunogen in a liposome context allows
the immune system to generate a productive humoral re-
sponse. While some of the theoretically possible responders in
the repertoire may be removed before they emerge into the
periphery due to mechanisms revealed through the B cell de-
velopmental studies of 4E10 and 2F5, others lacking polyreac-
tivity/autoreactivity can progress to LLPC. Thus, the MPER
target itself in a membrane context will not preclude the gen-
eration of protective antibodies. It is also notable that we dem-
onstrate here an ability to derive LLPC comprising several per-
centage points of the total BM niche, with persistence of
antibody production, over a very substantial fraction of the
mouse lifetime. These antibodies recognize an epitope map-
ping to the 10E8 region, spanning the region from S668 to the
end of the segment, but unlike 10E8, they are nonneutralizing.
The lack of neutralization activity is due in part to the fact that
they recognize the artificial C-terminal NH2 group (42). Elim-
inating this C-terminal NH2 group dependence while mimick-
ing a more native structural configuration of the MPER likely
will demand further modification of the MPER/liposome im-
munogen and may require inclusion of the transmembrane
domain of gp41. Collectively, our data suggest that the greatest
challenge to BNAb generation will be the design of vaccines to
foster the correct immunogenicity targeting the native MPER
exposed on the viral membrane-bound trimer.
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